nach oben

Erschienen in:

01.01.2011 | Original Article

Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT

verfasst von: Tomoro Hishiki, Tadashi Matsunaga, Fumiaki Sasaki, Michihiro Yano, Kohmei Ida, Hiroshi Horie, Satoshi Kondo, Ken-Ichiro Watanabe, Takaharu Oue, Tatsuro Tajiri, Arata Kamimatsuse, Naomi Ohnuma, Eiso Hiyama

Erschienen in: Pediatric Surgery International | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

In the recent years, surgical resection with pre- and/or postoperative chemotherapy has markedly improved the survival rate of hepatoblastoma patients. We herein report the results of patients treated with the current protocol of the Japanese Study Group for Pediatric Liver Tumor, JPLT-2.

Methods

A total of 279 patients with malignant liver tumor were enrolled in JPLT-2. Data from 212 hepatoblastoma cases were analyzed. PRETEXT I patients were treated with primary resection followed by low doses of cisplatin–pirarubicin (tetrahydropyranyl-adriamycin). Otherwise, patients received preoperative cisplatin–pirarubicin (CITA), followed by surgery and postoperative chemotherapy. Ifosfamide, pirarubicin, etoposide, and carboplatin (ITEC) were given as a salvage treatment. High-dose chemotherapy with hematopoietic stem cell transplantation (SCT) was reserved for patients with metastatic diseases.

Results

The 5-year overall survival rate (OS) in non-metastatic cases was 100% for PRETEXT I, 87.1% for PRETEXT II, 89.7% for PRETEXT III, and 78.3% for PRETEXT IV. The 5-year OS in metastatic cases was 43.9%. The outcome in non-metastatic PRETEXT IV cases was markedly improved, while the results of metastatic tumors remained poor.

Conclusions

JPLT-2 protocol achieved satisfactory survival among children with non-metastatic hepatoblastoma. New approaches are needed for patients with metastatic diseases.

Ortega JA, Douglass EC, Feusner JH et al (2000) Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol 18:2665–2675PubMed

Fuchs J, Rydzynski J, von Shweinitz D et al (2002) Pretreatment prognostic factors and treatment results in children with hepatoblastoma. A report from the German Cooperative Pediatric Liver Tumour Study HB94. Cancer 95:172–182CrossRefPubMed

Perilongo G, Shafford E, Maibach R et al (2004) Risk-adapted treatment for childhood hepatoblastoma: final report of the second study of the International Society of Paediatric Oncology––SIOPEL 2. Eur J Cancer 40:411–421CrossRefPubMed

Sasaki F, Matsunaga T, Iwafuchi M et al (2002) Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: a report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg 37:851–856CrossRefPubMed

Katzenstein HM, London WB, Douglass EC et al (2002) Treatment of unresectable and metastatic hepatoblastoma: a Pediatric Oncology Group Phase II Study. J Clin Oncol 20:3438–3444CrossRefPubMed

Matsunaga T, Sasaki F, Ohira M et al (2003) Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma. Pediatr Surg Int 19:142–146PubMed

Malogolowkin MH, Katzenstein H, Krailo MD et al (2006) Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol 24:2879–2884CrossRefPubMed

Czauderna P, Otte JB, Aronson DC et al (2005) Guidelines for surgical treatment of hepatoblastoma in the modern era––recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer 41:1031–1036CrossRefPubMed

Tagge EP, Tagge DU, Reyes J et al (1992) Resection, including transplantation, for hepatoblastoma and hepatocellular carcinoma: impact on survival. J Pediatr Surg 27:292–297CrossRefPubMed

10.

King DR, Ortega J, Campbell J et al (1991) The surgical management of children with incompletely resected hepatic cancer is facilitated by intensive chemotherapy. J Pediatr Surg 26:1074–1081CrossRefPubMed

11.

Perilongo G, Maibach R, Shafford E et al (2009) Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 361:1662–1670CrossRefPubMed

12.

Brown J, Perilongo G, Shafford E et al (2000) Pretreatment prognostic factors for children with hepatoblatoma––results from the International Society of Paediatric Oncology (SIOP) Study SIOPEL 1. Eur J Cancer 36:1418–1425CrossRefPubMed

13.

Aronson DC, Schnater JM, Staalman CR et al (2005) Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Grou p SIOPEL-1 study. J Clin Oncol 23:1245–1252CrossRefPubMed

14.

Meyers RL, Rowland JR, Krailo M et al (2009) Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 53:1016–1022CrossRefPubMed

15.

Koh E, Ueda Y, Nakamura T, Kobayashi A, Katsuta S, Takahashi H (2002) Apoptosis in young rats with adriamycin-induced cardiomyopathy––comparison with pirarubicin, a new anthracycline derivative. Pediatr Res 51:256–259CrossRefPubMed

16.

Zsíros J, Maibach R, Shafford E et al (2010) Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 28:2584–2590CrossRefPubMed

17.

Otte JB, Oritchars J, Aronson DC et al (2004) Liver transplantation for hepatoblastoma: results from the international society of pediatric oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 42:74–83CrossRefPubMed

18.

Otte JB, de Goyet JV, Reding R (2005) Liver transplantation for hepatoblastoma: indications and contraindications in the modern era. Pediatr Transplant 9:557–565CrossRefPubMed

19.

Reyes JD, Carr B, Dvorchik I et al (2000) Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. J Pediatr 136:795–804CrossRefPubMed

20.

Tanaka K, Uemoto S, Tokunaga Y et al (1993) Surgical techniques and innovations in living related liver transplantation. Ann Surg 217:82–91CrossRefPubMed

21.

Kasahara M, Ueda M, Haga H et al (2005) Living-donor liver transplantation for hepatoblastoma. Am J Transplant 5:2229–2235CrossRefPubMed

22.

Nishimura S, Sato T, Fujita N et al (2002) High-dose chemotherapy in children with metastatic hepatoblastoma. Pediatr Int 44:300–305CrossRefPubMed

23.

Yoshinari M, Imaizumi M, Hayashi Y et al (1998) Peripheral blood stem cell transplantation for hepatoblastoma with microscopical residue: a therapeutic approach for incompletely resected tumor. Tohoku J Exp Med 184:247–254CrossRefPubMed

24.

Kitahara S, Makuuchi M, Ishizone S et al (1995) Successful left trisegmentectomy for ruptured hepatoblastoma using intraoperative transarterial embolization. J Pediatr Surg 30:1709–1712CrossRefPubMed

25.

Iida T, Senaga M, Takeuchi Y et al (2004) Successful resection of a ruptured hepatoblastoma prior to chemotherapy: report of a case. Surg Today 34:710–714CrossRefPubMed

26.

Hara J, Osugi Y, Ohta H et al (1998) Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric tumors. Bone Marrow Transplant 22:7–12CrossRefPubMed

27.

Suita S, Tajiri T, Takamatsu H et al (2004) Improved survival outcome for hepatoblastoma based on an optimal chemotherapeutic regimen––a report from the study group for pediatric solid malignant tumors in the Kyushu area. J Pediatr Surg 39:195–198CrossRefPubMed

28.

von Schweinitz D, Hecker H, Harmas D et al (1995) Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma––a report from the German Cooperative Pediatric Liver Tumor Study HB-89. J Pediatr Surg 30:845–852CrossRef

29.

Katzenstein HM, Rigsby C, Shaw PH et al (2002) Novel therapeutic approaches in the treatment of children with hepatoblastoma. J Pediatr Hematol Oncol 24:751–755CrossRefPubMed

30.

Palmer RD, Williams DM (2003) Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11). Med Pediatr Oncol 41:78–80CrossRefPubMed

31.

Ijichi O, Ishikawa S, Shinkoda Y et al (2006) Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan. Pediatr Transplant 10(5):635–638CrossRefPubMed

32.

Bomgaars LR, Bernstein M, Krailo M et al (2007) Phase II trial of irinotecan in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol 25:4622–4627CrossRefPubMed

33.

Qayed M, Powell C, Morgan ER et al (2010) Irinotecan as maintenance therapy in high-risk hepatoblastoma. Pediatr Blood Cancer 54:761–763PubMed

Titel: Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT
verfasst von: Tomoro Hishiki
Tadashi Matsunaga
Fumiaki Sasaki
Michihiro Yano
Kohmei Ida
Hiroshi Horie
Satoshi Kondo
Ken-Ichiro Watanabe
Takaharu Oue
Tatsuro Tajiri
Arata Kamimatsuse
Naomi Ohnuma
Eiso Hiyama
Publikationsdatum: 01.01.2011
Verlag: Springer-Verlag
Erschienen in: Pediatric Surgery International / Ausgabe 1/2011
Print ISSN: 0179-0358
Elektronische ISSN: 1437-9813
DOI: https://doi.org/10.1007/s00383-010-2708-0

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT